Development of Reagents for Application of At-211 to Targeted Radionuclide Therapy of Cancer

Wilbur, D. Scott

关键词: ASTATINE 211;    IN VIVO;    NEOPLASMS;    RADIATION DOSES;    RADIOISOTOPES;    STABILITY;    THERAPY Targeted Radionuclide Therapy;    Astatine-211;    Radiolabeling;    Therapeutic Radiopharmaceuticals;   

DOI  :  10.2172/1032019
RP-ID  :  DOE/ER63970
PID  :  OSTI ID: 1032019
Others  :  TRN: US1200854

美国|英语

来源: SciTech Connect

【 摘 要 】

This grant covered only a period of 4 months as the major portion of the award was returned to DOE due to an award of funding from NIH that covered the same research objectives. A letter regarding the termination of the research is attached as the last page of the Final Report. The research conducted was limited due to the short period of this grant, but the results obtained in that period are outlined in the Final Report. The studies addressed in the research effort were directed at a problem that is of critical importance to the in vivo application of the alpha-particle emitting radionuclide At-211. That problem, low in vivo stability of many astatinated molecules, severely limits the use of At-211 in therapeutic applications. The advances sought in the studies were expected to expand the types of biomolecules that can be used as carriers of At-211, and provide improved in vivo targeting of the radiation dose compared with the dose delivered to normal tissue.